Enanta Pharmaceuticals Inc SEC Filings

Enanta Pharmaceuticals reported a material event in an 8-K that discloses an Underwriting Agreement dated September 30, 2025, legal opinion and consent from Foley Hoag LLP, and an embedded interactive cover page XBRL file. The filing restates standard forward-looking statement disclaimers and indicates the company will not update forward-looking statements except as required by law. The document is signed by Jay R. Luly, Ph.D., President and Chief Executive Officer, with a filing date of October 1, 2025.

Enanta Pharmaceuticals (ENTA) prospectus supplement describes a securities offering that would issue shares at $10.00 per share with aggregate proceeds shown as $65,000,000 (and an underwriting fee example of $0.60 per share or $3,900,000). Net proceeds are intended to fund clinical trials, research and development, working capital and general corporate purposes. The filing highlights ongoing revenue from an AbbVie collaboration and a 2023 royalty sale that help fund Enanta’s R&D programs. Clinical programs discussed include oral STAT6 inhibitors (a development candidate expected to be nominated in the second half of 2025), zelicapavir safety data showing mostly mild adverse events, and disease burdens for RSV and COVID-19 with specific hospitalization and mortality ranges for RSV in older adults. The supplement details a 60-day lock-up for insiders, exceptions (including Rule 10b5-1 plans), tax withholding rules for non-U.S. holders (generally 30% on dividends absent treaty relief), and references to incorporated reports and underwriting disclosures.

Enanta Pharmaceuticals (ENTA) prospectus supplement excerpts describe an offering with underwriter arrangements, lock-up agreements and planned use of proceeds to fund clinical trials, research and general corporate purposes. The company notes ongoing royalties from an AbbVie collaboration and proceeds from an April 2023 royalty sale that support its R&D programs.

The filing highlights clinical and preclinical programs including a STAT6 oral inhibitor program with a development candidate expected to be nominated in the second half of 2025, zelicapavir safety outcomes (mostly mild AEs; diarrhea 3.3%, asthma 2.5%) and antiviral efficacy signals versus placebo. The supplement also summarizes U.S. federal tax withholding rules for non-U.S. holders and customary risk and forward-looking statement disclaimers.

Enanta Pharmaceuticals filed an Form 8-K reporting a proof-of-concept, signal-finding study of oral antiviral zelicapavir for RSV. Patients were enrolled within 72 hours of symptom onset and received 800mg once daily for 5 days or placebo. The trial measured symptoms using the RiiQTM scale covering 13 RSV symptoms and assessed a four-symptom lower respiratory tract disease (LRTD) subset as the primary endpoint, defined as time to resolution to mild, with predefined complete-resolution analyses also conducted. Secondary measures included total RiiQTM score, patient global impressions, virology, safety, and hospitalization rate. The filing references the company’s 2024 10-K and includes the company caution on forward-looking statements. The 8-K is signed by Jay R. Luly, Ph.D. and dated September 29, 2025.

Enanta Pharmaceuticals (ENTA) Form 3: Kathleen S. Capps reports beneficial ownership tied to her role as Executive Director, Accounting & Controller and director/officer of Enanta. She directly holds 5,829 shares represented by unvested RSUs and a series of stock options exercisable between 04/01/2026 and 11/27/2034 covering named share amounts. The filing lists vesting schedules for RSUs and exercise prices for each option.

Enanta Pharmaceuticals (ENTA) Form 3: Harry R. Trout III reported ownership of 10,912 shares of Enanta common stock, consisting of 762 vested shares and 10,150 shares underlying unvested restricted stock units (RSUs). The RSUs vest in scheduled installments between December 1, 2025 and subsequent annual or multi-year installment schedules described in the filing. Mr. Trout also holds a series of stock options covering 53,966 underlying shares with exercise prices ranging from $8.83 to $81.20; one option grant is 100% vested and exercisable and other grants vest quarterly over four years from their grant dates. The filing was signed by an attorney-in-fact on Mr. Trout's behalf.